A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
Dimethyl fumarate
multiple sclerosis
teriflunomide
treatment response
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
pubmed:
4
6
2021
medline:
17
3
2022
entrez:
3
6
2021
Statut:
ppublish
Résumé
Teriflunomide and dimethyl fumarate (DMF) are first-line disease-modifying treatments for multiple sclerosis with similar labels that are used in comparable populations. The objective of this study was to compare the effectiveness and persistence of teriflunomide and DMF in a Swedish real-world setting. All relapsing-remitting multiple sclerosis (RRMS) patients in the Swedish MS registry initiating teriflunomide or DMF were included in the analysis. The primary endpoint was treatment persistence. Propensity score matching was used to adjust comparisons for baseline confounders. A total of 353 teriflunomide patients were successfully matched to 353 DMF. There was no difference in the rate of overall treatment discontinuation by treatment group across the entire observation period (hazard ratio (HR) = 1.12; 95% confidence interval (CI) = 0.91-1.39; This population-based real-world study reports similarities in treatment persistence, clinical effectiveness and quality of life outcomes between teriflunomide and dimethyl fumarate.
Sections du résumé
BACKGROUND
BACKGROUND
Teriflunomide and dimethyl fumarate (DMF) are first-line disease-modifying treatments for multiple sclerosis with similar labels that are used in comparable populations.
OBJECTIVES
OBJECTIVE
The objective of this study was to compare the effectiveness and persistence of teriflunomide and DMF in a Swedish real-world setting.
METHODS
METHODS
All relapsing-remitting multiple sclerosis (RRMS) patients in the Swedish MS registry initiating teriflunomide or DMF were included in the analysis. The primary endpoint was treatment persistence. Propensity score matching was used to adjust comparisons for baseline confounders.
RESULTS
RESULTS
A total of 353 teriflunomide patients were successfully matched to 353 DMF. There was no difference in the rate of overall treatment discontinuation by treatment group across the entire observation period (hazard ratio (HR) = 1.12; 95% confidence interval (CI) = 0.91-1.39;
CONCLUSION
CONCLUSIONS
This population-based real-world study reports similarities in treatment persistence, clinical effectiveness and quality of life outcomes between teriflunomide and dimethyl fumarate.
Identifiants
pubmed: 34080926
doi: 10.1177/13524585211019649
pmc: PMC8795225
doi:
Substances chimiques
Crotonates
0
Hydroxybutyrates
0
Immunosuppressive Agents
0
Nitriles
0
Toluidines
0
teriflunomide
1C058IKG3B
Dimethyl Fumarate
FO2303MNI2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
237-246Références
Ther Adv Neurol Disord. 2018 Sep 10;11:1756286418796404
pubmed: 30210582
Epidemiology. 2019 Mar;30(2):230-233
pubmed: 30721167
Mult Scler. 2012 Sep;18(9):1278-89
pubmed: 22307384
Lancet Neurol. 2014 Mar;13(3):247-56
pubmed: 24461574
J Neurol. 2020 Oct;267(10):3008-3020
pubmed: 32506391
J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468
pubmed: 30636699
N Engl J Med. 2011 Oct 6;365(14):1293-303
pubmed: 21991951
N Engl J Med. 2012 Sep 20;367(12):1087-97
pubmed: 22992072
Lancet Neurol. 2014 Oct;13(10):977-86
pubmed: 25192851
Lancet. 2008 Oct 25;372(9648):1463-72
pubmed: 18970976
N Engl J Med. 2012 Sep 20;367(12):1098-107
pubmed: 22992073
Neurology. 2019 Aug 13;93(7):e635-e646
pubmed: 31300547
Neurology. 2019 Apr 16;92(16):e1811-e1820
pubmed: 30877188
Acta Neurol Scand. 2015;132(199):11-9
pubmed: 26046553
Brain. 2001 May;124(Pt 5):962-73
pubmed: 11335698
Mult Scler. 2014 May;20(6):705-16
pubmed: 24126064
Curr Med Res Opin. 2014 Apr;30(4):613-27
pubmed: 24195574
Neurology. 2006 Mar 28;66(6):894-900
pubmed: 16567708
Lancet Neurol. 2019 Mar;18(3):269-285
pubmed: 30679040